Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 8/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.38 |
| ▸ | CETP | P11597 | 6/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4452503 | 0.84 | P2RX7 (0.39) | PDE3BPDE3AHDAC1HDAC8HDAC6 | |
| SCHEMBL4458260 | 0.81 | PDE3B (0.41) | PDE3BPDE3A | |
| SCHEMBL4472192 | 0.77 | GRM2 (0.35) | HCRTR1HCRTR2PDE3BPDE3ACETP | |
| SCHEMBL4449982 | 0.75 | HDAC1 (0.39) | HCRTR1HCRTR2PDE3BPDE3AHDAC1 | |
| SCHEMBL5286742 | 0.72 | IDH1 (0.43) | — | |
| SCHEMBL5281444 | 0.72 | IDH1 (0.43) | — | |
| SCHEMBL2615701 | 0.72 | IDH1 (0.43) | — | |
| SCHEMBL4463022 | 0.72 | MDM2 (0.39) | PDE3BPDE3A | |
| SCHEMBL2308885 | 0.70 | BRD4 (0.40) | — | |
| SCHEMBL10308940 | 0.69 | MTOR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | HCRTR1 3435/4885HCRTR2 3347/4885PDE3B 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.